Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome

Documenta Ophthalmologica

Volumn 106, Issue 3, 2003, Pages 215-223

  Janciauskiene, Sabina ^a   Krakau, Torsten ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

1 Antichymotrypsin; 1 Antitrypsin; Alz heimer's peptide; Cataract; Exfoliation syndrome; Glaucoma

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALZHEIMER PEPTIDE ABETA1-42; ANTIBODY; ANTIBODY CONJUGATE; IMMUNOGLOBULIN; PEPTIDE; PEROXIDASE; PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; AQUEOUS HUMOR; ARTICLE; BIOCHEMISTRY; CATARACT; CATARACT EXTRACTION; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ELECTROPHORESIS; EXFOLIATION SYNDROME; EYE INFLAMMATION; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; NERVE CELL DEGENERATION; OPEN ANGLE GLAUCOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PSEUDOEXFOLIATION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALPHA 1-ANTICHYMOTRYPSIN; ALPHA 1-ANTITRYPSIN; AMYLOID BETA-PROTEIN; AQUEOUS HUMOR; BLOTTING, WESTERN; CATARACT; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXFOLIATION SYNDROME; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SERINE PROTEINASE INHIBITORS;

EID: 0344951179     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022949121078     Document Type: Article

References (55)

1. Cristini G. The rationale of ocular hypertension in glaucoma, the common basis for hypertension and nervous atrophy. XVI Concilium Ophthal. London 1951: 865-71.
2. Khalil AK, Kubota T, Tawara A, Inomata H. Early changes in iris blood vessels in exfoliation syndrome. Curr Eye Res 1998; 17: 1124-34.
3. Cristini G, Consolani A, Lazzari F. Ocular hypertension in primary glaucoma: A new hypotetis. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1980; 213: 283-90.
4. Ducker HJ. Pathogenesis of the pseudoexfoliation syndrome. Fortscher Ophthalmol 1982; 79: 142-43.
5. Vesti E, Kivel T. Exfoliation syndrome and exfoliation glaucoma. Prog Retin Eye Res 2000; 19: 345-68.
6. Brooks A, Gillies WE. Fluorescein angiography and fluorometry of the iris in pseudoexfoliation of the lens capsule. Br J Ophthalmol 1983; 67: 249-54.
7. Kuchle M, Nguyen NX, Hannappel E, Naumann GO. The blood-aqueous barrier in eyes with pseudoexfoliation syndrome. Ophthalmic Res 1995; 27: 136-42.
8. Ringvold A. Pseudo-exfoliation material-an amyloid like substance. Exp Eye Res 1973; 17: 289-99.
9. Ringvold A, Husby G, Pettersen S. Electrophoretic study of proteins associated with pseudo-exfoliation syndrome. Acta Ophthal 1989; 67: 724-26.
10. Morrison BM, Hof PR, Morrison JH. Determinants of neuronal vulnerability in neurodegenerative diseases. Ann Neurol 1998; 44: 32-44.
11. Naumann GO, Schlotzer-Schrehardt U, Kuchle M. Pseudo-exfoliation syndrome for the comprehensive ophthalmologist. Intraocular and systemic manifestations. Ophthalmology 1998; 105: 951-68.
12. Koliakos G, Konstas GP, Triantos A, Ritch R. Increased growth factor activity in the aqueous humour of patients with exfoliation syndrome. Graefes Arch Clin Exp Ophthalmol 2000; 238: 491-95.
13. Sawa M, Tsurimaki Y, Tsuru T, Shimizu H. New quantitative method to determine protein concentration and cell number in aqueous in vivo. Jpn J Ophthalmol 1988; 32: 132-42.
14. Damji KF, Bains HS, Stefansson E, Loftsdottir M, Sverrisson T, Thorgeirsson E, Jonasson F, Gottfredsdottir M, Allingham RR. In pseudoexfoliation syndrome inherited? A review of genitic and nongenitic factors and a new observation. Ophthalmic Genet 1998; 19: 175-85.
15. Lowe J, Landon M, Pike I, Spendlove I, McDermott H, Mayer RJ. Dementia with beta-amyloid deposition: Involvement of alpha B-crystallin supports two main diseases. Lancet 1990; 336: 515-16.
16. Vickers JC. The cellular mechanism underlying neuronal degeneration in glaucoma: Parallels with Alzheimer's disease. Aust N Z J Ophthalmol 1997; 25: 105-9.
17. Loffler KU, Edward DP, Tso MO. Immunoreactivity against tau, amyloid precursor protein, and beta amyloid in the human retina. Invest Ophthalmol Vis Sci 1995; 36: 24-31.
18. Cooper NR, Bradt BM, O'Barr S, Yu JX. Focal inflammation in the brain: Role in Alzheimer's disease. Immunol Res 2000; 21: 159-65.
19. Emmerling MR, Morganti-Kossman MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM, Roher AE, Raby CA. Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury. Ann N Y Acad Sci 2000; 903: 118-22.
20. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 2000; 130: 184-208.
21. Tomiyama T, Corder EH, Mori H. Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease. Cell Mol Life Sci. 1999; 56: 268-79.
22. Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, Potter H α-1-Antichymotrypsin promotes β-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci 2000; 21: 1444-51.
23. Frederikese PH, Ziegler SJ Jr, Fransworth PN, Carper DA. Prion protein expression in mammalian lenses. Curr Eyes Res 2000; 20: 137-43.
24. Frederikese PH, Garland D, Ziegler SJ Jr, Piatigorsky J. Oxidative stress in increases produktion on β-Amyloid precursor protein and β-Amyloid (Aβ) in mammalian lenses an Aβ has toxic effects on lens Epithelial cells. Am Soc Biochem Molec Biol Inc 1996; 271: 10169-74.
25. Frederikese PH, Zigler JS Jr. Presenilin expression in the ocular lens. Curr Eye Res 1998; 17: 947-52.
26. 1 - antichymotrypsin in brain dysfunction and injury. Res Immunol 1992; 143: 631-36.
27. 1 - antichymotrypsin and transforms in from inhibitor to substrate. J Biol Chem 1998; 273: 28360-64.
28. Janciauskiene S, Wright HT. Inflammation, antichymotrypsin, and lipid metabolism: Autogenic etiology of Alzheimer's disease. Bioessays 1998; 20: 1039-46.
29. Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 1993; 61: 298-305.
30. Licastro F, Sirri V, Trere D, Davis LJ. Monomeric and polymeric forms of alpha-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease. Dement Geriatr Cogn Disord 1997; 8: 337-42.
31. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655-709.
32. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY Reference distributions for the positive acute phase serum proteins, alpha1-acid glycoprotein (orosomucoid), alpha1-antitrypsin, and haptoglobin: A practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 2000; 14: 284-92.
33. Boskovic G, Twining SS. Local control of alpha1-proteinase inhibitor levels: Regulation of alpha1-proteinase inhibitor in the human cornea by growth factors and cytokines. Biochim Biophys Acta 1998; 1403: 37-46.
34. Harding JJ. Alzheimer's disease and cataract: Common threads. Alzheimer Dis Assoc Disord 1993; 7: 55-6.
35. Harding JJ. Cataract, Alzheimer's disease, and other conformational diseases. Curr Opin Ophthalmol 1998; 9: 10-13.
36. Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, Hsu CY Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 2001; 21: RC118.
37. Sutton ET, Thomas, Bryant MW, Landon CS, Newton CA, Rhodin JA. Amyloid-beta peptide induced inflammatory reaction is mediated by the cytokines tumor necrosis factor and interleukin-1. J Submicrose Cytol Pathol 1999; 313: 13-23F.
38. Goldsbury CS, Wirtz S, Muller SA, Sunderji S, Wicki P, Aebi U, Frey P. Studies on the in vitro assembly of a beta 1-40: Implications for the search for a beta fibril formation inhibitors. J Struct Biol 2000; 130: 217-31.
39. Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Naslund J, Richards G, Huber W, Dobeli H, Nordstedt C. Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 1999; 274: 15990-5.
40. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000; 1502: 76-84.
41. Ritch R. Exfoliation syndrome and occludable angles. Trans Am Ophthalmol Soc 1994; 92: 845-944.
42. Lindblom B, Thorburn W. Functional damage at diagnosis of primary open angle glaucoma. Acta Ophthalmol (Copenhagen) 1984; 62: 223-9.
43. Hu DN, Ritch R. Hepatocyte growth factor is increased in the aqueous humor of glaucomatous eyes. J Glaucoma 2001; 10: 152-7.
44. Panayotou G, End P, Aumailley M, Timpl R, Engel J. Domains of laminin with growth-factor activity. Cell 1989; 56: 93-101.
45. Villa A, Latasa MJ, Pascual A. Nerve growth factor modulates the expression and secretion of beta-amyloid precursor protein through different mechanisms in PC12 cells. J Neurochem 2001; 77:1077-84.
46. Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 2001; 894: 21-30.
47. Strohmeyer R, Rogers J. Molecular and cellular mediators of Alzheimer's disease inflammation. J Alzheimer's Dis 2001; 3: 131-57.
48. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol 1999; 43(Suppl): S43-50.
49. Gooptu B, Hazes B, Chang WS, Dafforn TR, Carrell RW, Read RJ, Lomas DA. Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: Implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA 2000; 97: 67-72.
50. Janciauskiene S, Eriksson S, Wright HT. A specific structural interaction of Alzheimer's peptide A beta 1-42 with alpha 1-antichymotrypsin. Nat Struct Biol 1996; 3: 668-71.
51. Saito H, Shultz LD, Sinha M, Papaconstantinou J. Induction of the alpha(1)-antichymotrypsin gene in the brain associated with TGF-beta1 deficiency or systemic administration of endotoxin. Biochem Biophys Res Commun 1999; 263: 270-5.
52. Ritch R. Exfoliation syndrome. Curr Opin Ophthalmol 2001; 12: 124-30.
53. Stefan C, Cucea R, Popescu A, Stoenescu D. Cataract and exfoliative syndrome. Oftalmologia 1998; 42: 33-6.
54. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001; 42: 1787-94.
55. Linner E, Popovic V, Gottfries CG, Jonsson M, Sjogren M, Wallin A. The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. Acta Ophthalmol Scand 2001; 79: 283-5.